Frequently Asked Questions
The questions below reflect the most common areas of enquiry from supply chain, QA, and CMC teams. If your question is not covered here, our team is available to respond directly.
Can PharmaGend support a company that already has an established commercial manufacturer in place?
Yes. PharmaGend supports companies seeking to strengthen supply resilience, reduce single-source exposure, or add geographic diversification. The onboarding process — programme assessment, configuration planning, technology transfer, and validation — is designed to establish a fully validated, inspection-ready supply arrangement without disrupting existing manufacturing.
How long does it typically take to onboard PharmaGend as a commercial supplier?
Timelines vary by product and follow two phases.
Scope and service agreement discussions take 1–3 months, covering needs assessment, capability review, and pricing.
Technology transfer takes 6–12 months or longer, covering gap analysis, methods transfer, batch manufacturing, stability data generation, and regulatory filing support.
Key factors include product complexity, regulatory pathway, material availability, and information readiness.
What documentation is required to initiate RFQ?
An initial assessment requires dosage form, formulation overview, current batch size, and regulatory filing status. A full technical package is not required at this stage. Our team will confirm specifics once the scope is agreed.
Why manufacture in Singapore rather than a lower-cost jurisdiction?
The relevant comparison is total cost of supply, not unit cost. Accounting for supply reliability, regulatory performance, and logistics efficiency, Singapore’s stable, well-regulated manufacturing base delivers a more predictable and defensible cost profile over the full commercial lifecycle.
Which markets can PharmaGend supply from Singapore?
PharmaGend holds approvals from HSA, FDA, and Swissmedic. Singapore’s PIC/S membership supports alignment with a broad range of additional regulated markets. Our team can confirm current approval status and discuss the regulatory pathway for additional geographies.
How does Singapore’s regulatory environment compare to other Asian manufacturing jurisdictions?
Singapore’s HSA is a single, central regulator with strong alignment to FDA, EMA, and other major authorities through PIC/S membership — providing clarity and consistency that translates into a more predictable inspection environment and a compliance record that is straightforward to defend.
How does PharmaGend manage post-approval changes?
Changes are managed within a structured framework covering impact assessment, cross-functional review, documented approval, and validated implementation — with your QA and CMC teams kept informed throughout.
Can PharmaGend accommodate new SKUs or additional strengths within an existing commercial programme?
Yes. Our configured manufacturing model supports multi-SKU programmes and lifecycle extensions, managed through the same change control and validation framework — without disrupting supply of existing SKUs.